| Biomarker ID | 1454 |
| PMID | 24978824 |
| Year | 2014 |
| Biomarker | Prostate Health Index (phi) |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Negative Vs PCa (Segregated on the basis of Prostate Volume) |
| Type of Biomarker | Diagnostic |
| Cohort | 220 subjects with PSA lower than 10 μg/L were enrolled. 102 subjects had a negative biopsy and 118 had PCa |
| Senstivity | NA |
| Specificity | NA |
| AUC | Prostate Volume ≤ 35: 0.818 (95% CI: 0.704–0.933) 36 ≤ Prostate Volume ≤ 50 : 0.716 (95% CI: 0.577–0.855) Prostate Volume >50: 0.654 (95% CI: 0.543–0.766)All Patients: 0.748 (95% CI: 0.684–0.812) |
| Accuracy | NA |
| Level Of Significance | Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009 |
| Method Used | Immunoassays |
| Clinical | No |
| Remarks | phi = p2PSA/fPSA × √tPSA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |